Abstract

Polymers of lys (plys) and arg (parg) were found to be efficient inhibitors of the formation of complexes between low density lipoprotein (LDL) and human chondroitin-6-sulfate-rich proteoglycans. Displacement curves indicate that efficiency was dependent on molecular weight. Inclusion of alanine in the polymer up to a 1:1 molar ratio (plys,ala) has a moderate effect on displacing capacity. Poly-L-lys (plys) and poly-L-arg (parg) exhibited similar displacing ability. Inclusion of tryptophan in plys and parg diminished their effect, whereas inclusion of serine in plys,ser (3:1) improved it. Plys (18.3 kD) stimulates LDL binding to human fibroblasts. This may be due to the association of polylysine to LDL, leading to an increase in its positive charge. These more positively charged LDL may have an increased association with the negatively charged region of the apolipoprotein B/E receptor. Perfusion experiments on rabbit aortic segments were used to measure the influx of 125I-LDL into the intima and to study the effect of basic polypeptides. Plys in a 10:1 molar ratio decreased the LDL uptake by approximately 25% when added to the system together with the LDL or in experiments in which the tissue segments were pre-perfused with plys, and LDL was added after elimination of the plys. The results suggest that polycationic polypeptides, due to their strong affinity for sulfated proteoglycans, interfere with the interactions of LDL with components of the arterial extracellular matrix.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.